The vaccine maker, which has partnered with OpenAI since 2023, is rethinking how it does workforce planning thanks to the ...

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a study, but U.S. government regulators ...

Moderna is being audited by the PMCPA after yet again being found to have brought discredit on the pharma industry, putting ...

We recently published a list of Billionaire David E. Shaw’s 10 Small-Cap Stock Picks with Huge Upside Potential. In this ...

MM+M Women of Distinction honoree, announced Monday morning that she has joined Medtronic Diabetes as its chief marketing ...

Moderna also hopes that combining the shots will help improve vaccine rates. Poland, however, is not sure people will like ...

In a study published in the Journal of the American Medical Association, researchers from Moderna reported that the new combo ...

Biotechnology company Moderna (NASDAQ:MRNA) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 35.3% year on year to $108 million. The company’s full-year revenue ...

Moderna MRNA kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, the steep decline in revenues raises concerns. While sales of its COVID ...

The Trump administration stopped the study. Researchers from vaccine-maker Moderna reported in a study published Wednesday that the new combo shot generated a stronger immune response against ...